Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 16/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 14/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11994442 | 0.92 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HDAC3HDAC4HDAC1 | |
| SCHEMBL2401029 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL11994100 | 0.88 | HSP90AA1 (0.82) | HSP90AA1HSP90AB1HDAC3HDAC4HDAC1 | |
| SCHEMBL2402099 | 0.88 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL11994098 | 0.87 | HSP90AA1 (0.78) | HSP90AA1HSP90AB1HDAC3HDAC4HDAC1 | |
| SCHEMBL11994096 | 0.87 | HSP90AA1 (0.83) | HSP90AA1HSP90AB1HDAC3HDAC4HDAC1 | |
| SCHEMBL5322935 | 0.87 | HSP90AB1 (0.81) | HSP90AA1HSP90AB1HDAC3HDAC4HDAC1 | |
| SCHEMBL2400526 | 0.87 | HSP90AA1 (0.85) | HSP90AA1HSP90AB1 | |
| SCHEMBL2398304 | 0.87 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL2399719 | 0.87 | HSP90AA1 (0.78) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | claimed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | claimed |
| US-9718793-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (R&D) LTD. (GB) | 2017-08-01 | — | — | US | claimed |
| US-20130289026-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2013-10-31 | — | — | US | claimed |
| US-8507480-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (R&D) LIMITED (GB) | 2013-08-13 | — | — | US | claimed |
| US-8450310-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (R&D) LIMITED (GB) | 2013-05-28 | — | — | US | claimed |
| US-20120252797-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2012-10-04 | — | — | US | claimed |
| US-20100179138-A1 | Isozazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-07-15 | — | — | US | claimed |
| US-7705027-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-04-27 | — | — | US | claimed |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2006-10-26 | — | — | US | claimed |
| EP-1611112-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | Vernalis (Cambridge) Limited (GB) | 2006-01-04 | — | — | EP | claimed |
| WO-2004072051-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-08-26 | — | — | WO | claimed |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-7705027-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| EP-1611112-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | Vernalis (Cambridge) Limited (GB) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004072051-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252797-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HDAC3 1336/4885 |
| US-20100179138-A1 | Isozazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885HDAC3 764/4885 |
| US-20130289026-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885HDAC3 957/4885 |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885HDAC3 1029/4885 |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885HDAC3 967/4885 |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885HDAC3 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.